Close Menu

NEW YORK – Noninvasive prenatal diagnostics firm Ravgen has sued Natera for alleged infringement of two of its patents around cell-free DNA testing for genetic disorders.

In its complaint, filed on Monday in the US District Court for the Western District of Texas Waco Division, the Columbia, Maryland-based company claimed that Natera infringes its US Patents No. 7,727,720 and 7,332,277, both titled "Methods for detection of genetic disorders."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.